Skandinaviska Enskilda Banken (SEB)
ZNTL icon

Skandinaviska Enskilda Banken (SEB)’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Skandinaviska Enskilda Banken (SEB)’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-22,800
Closed -$643K – 999
2023
Q2 		$643K Sell
22,800
-23,200
-50% -$557K ﹤0.01% 758
2023
Q1 		$791K Buy
+46,000
New +$932K 0.01% 723

Other funds holding ZNTL

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Skandinaviska Enskilda Banken (SEB)'s ZNTL Position: Q3 2023 in Review

Skandinaviska Enskilda Banken (SEB) sold out of Zentalis Pharmaceuticals (ZNTL) in Q3 2023, closing a stake of 22,800 shares — an estimated $643K sold.

Skandinaviska Enskilda Banken (SEB) first reported a position in ZNTL in Q1 2023 and held it in 2 quarters. The position peaked at $791K in Q1 2023. 137 funds tracked by Wall St. Rank hold ZNTL as of Q3 2023.

  • Skandinaviska Enskilda Banken (SEB) reported no remaining Zentalis Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Skandinaviska Enskilda Banken (SEB) sold 22,800 Zentalis Pharmaceuticals shares in Q3 2023, an estimated $643K.
  • Skandinaviska Enskilda Banken (SEB) first reported a position in Zentalis Pharmaceuticals in Q1 2023 and held it in 2 quarters.
  • Skandinaviska Enskilda Banken (SEB)'s Zentalis Pharmaceuticals position peaked at $791K in Q1 2023.
  • 137 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q3 2023.

Based on Skandinaviska Enskilda Banken (SEB)'s 13F filing for Q3 2023, filed 9 Nov 2023.